Why the study?
Does ticagrelor reduce the composite of cardiac death, myocardial infarction and stroke compared with clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention?
Population
Patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention
Comparison
Ticagrelor vs Clopidogrel
Design
Editorial
Key result
This editorial discusses recent evidence questioning the role of ticagrelor as a first-line antiplatelet option in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Authors
Loading...
Questions ticagrelor first-line role in ACS-PCI; leaves open whether recent data warrant guideline revision.
Does ticagrelor reduce the composite of cardiac death, myocardial infarction and stroke compared with clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention?
An editorial discussing recent evidence that questions the guideline-recommended role of ticagrelor as a first-line antiplatelet option in ACS patients undergoing PCI.
Davide Capodanno (2017) conducted an editorial in Acute coronary syndrome (ACS). Prasugrel and ticagrelor (Dual antiplatelet therapy) vs. Clopidogrel was evaluated on Composite of cardiac death, myocardial infarction and stroke. This editorial discusses recent evidence questioning the role of ticagrelor as a first-line antiplatelet option in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: